Wound Healing News and Research

RSS

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Cell migration is an important process in the development of organisms, as well as during immune surveillance and wound healing. For cancer development, the potential of cells to migrate or to grow invasively is, in addition to proliferation, the most important disease-causing factor. The inhibition of cell migration is a key target of the new anti-inflammatory therapies.

25 Nov 2009

Shareholders approve Derma Sciences' reverse stock split

Derma Sciences, Inc. a specialty medical device/pharmaceutical company focused on advanced wound care, announced today that its shareholders granted Derma Sciences' Board of Directors authority to implement a reverse stock split in the range of between 1-to-5 and 1-to-10.

25 Nov 2009

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Stents that keep weakened and flabby arteries from collapsing have been true life-savers. But after six months, those stents are no longer needed -- once the arteries are strengthened, they become unnecessary. Previously, doctors had no choice but to leave them in place.

25 Nov 2009

U.S. Patent Office approves multiple patent claims from Helix BioMedix

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.

20 Nov 2009

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg.

19 Nov 2009

Pre-clinical data of GM1485 to be presented by GliaMed

GliaMed, Inc., a development stage biopharmaceutical company, today announced that Dr. David Weinstein, chief scientific officer and company founder, will present pre-clinical data demonstrating acceleration of wound healing through the in vivo induction and recruitment of stem cells at the Stem Cells USA & Regenerative Medicine Congress in Washington, D.C.

18 Nov 2009

Advanced BioHealing commences efficacy trial of Dermagraft in the treatment of VLUs

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that it has initiated a pivotal trial of Dermagraft® in subjects with venous leg ulcers (DEVO-Trial) to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers (VLUs). Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.

4 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

UT Southwestern ophthalmologist receives 2009 Castroviejo Medal

Dr. H. Dwight Cavanagh, vice chairman of ophthalmology at UT Southwestern Medical Center, has been named the 2009 recipient of the prestigious Castroviejo Medal, one of the top ophthalmology prizes in the world.

30 Oct 2009

Comparative study of chronic wound treatment completed

The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to Hemospray treatment for ethical reasons.

30 Oct 2009

Prospera Technologies presents data on its Gauze vs. Foam based NPWT research

Prospera Technologies announced today that, at the Clinical Symposium on Advances in Skin & Wound Care in San Antonio, Texas, Oct 22-25, 2009, Malin Malmsjo MD., Ph.D. of Lund University in Lund, Sweden, presented significant new research comparing the differences and quality of granulation tissue in foam versus gauze based NPWT.

29 Oct 2009

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix, Inc., a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.

28 Oct 2009

Probiotic therapy can be effective for treating intestinal disorders

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment.

26 Oct 2009